转移性肾细胞癌的影像学诊断。
Imaging for Metastatic Renal Cell Carcinoma.
机构信息
Department of Radiology, NYU Langone Medical Center, New York, NY 10016, USA.
Department of Radiology, NYU Langone Medical Center, New York, NY 10016, USA; Department of Population Health NYU Langone Medical Center, New York, NY 10016, USA.
出版信息
Urol Clin North Am. 2020 Aug;47(3):281-291. doi: 10.1016/j.ucl.2020.04.005. Epub 2020 Jun 11.
Abstract
Patients with renal cell carcinoma may develop metastases after radical nephrectomy, and therefore monitoring with imaging for recurrent or metastatic disease is critical. Imaging varies with specific suspected site of disease. Computed tomography/MRI of the abdomen and pelvis are mainstay modalities. Osseous and central nervous system imaging is reserved for symptomatic patients. Radiologic reporting is evolving to reflect effects of systemic therapy on lesion morphology. Nuclear medicine studies compliment routine imaging as newer agents are evaluated for more accurate tumor staging. Imaging research aims to fill gaps in treatment selection and monitoring of treatment response in metastatic renal cell carcinoma.
摘要
肾细胞癌患者在根治性肾切除术后可能发生转移，因此通过影像学监测复发或转移疾病至关重要。影像学检查因具体疑似病变部位而异。腹部和盆腔 CT/MRI 是主要方式。有症状的患者保留骨和中枢神经系统成像。放射学报告正在发展，以反映全身治疗对病变形态的影响。核医学研究补充了常规影像学检查，因为新的药物正在评估中，以更准确地进行肿瘤分期。影像学研究旨在填补转移性肾细胞癌治疗选择和监测方面的空白。
相似文献
1
Imaging for Metastatic Renal Cell Carcinoma.转移性肾细胞癌的影像学诊断。
Urol Clin North Am. 2020 Aug;47(3):281-291. doi: 10.1016/j.ucl.2020.04.005. Epub 2020 Jun 11.
2
Positron emission tomography for prostate, bladder, and renal cancer.用于前列腺癌、膀胱癌和肾癌的正电子发射断层扫描。
Semin Nucl Med. 2004 Oct;34(4):274-92. doi: 10.1053/j.semnuclmed.2004.06.004.
3
Utility of Pelvic CT for Surveillance of T2-T4 Renal Cell Carcinoma After Nephrectomy With Curative Intent.盆腔 CT 在根治性肾切除术后 T2-T4 期肾细胞癌监测中的应用。
AJR Am J Roentgenol. 2018 May;210(5):1088-1091. doi: 10.2214/AJR.17.18898. Epub 2018 Feb 28.
4
Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.[F-18] -氟代脱氧葡萄糖正电子发射断层扫描在肾细胞癌再分期中的诊断作用
Clin Nephrol. 2003 Dec;60(6):395-400. doi: 10.5414/cnp60395.
5
Imaging in metastatic renal cell carcinoma.转移性肾细胞癌的影像学检查
AJR Am J Roentgenol. 2007 Aug;189(2):360-70. doi: 10.2214/AJR.07.2077.
6
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.正电子发射断层扫描成像在代谢活跃型肾细胞癌中的作用。
Curr Urol Rep. 2019 Aug 29;20(10):56. doi: 10.1007/s11934-019-0932-2.
7
8
Staging, surveillance, and evaluation of response to therapy in renal cell carcinoma: role of MDCT.肾细胞癌的分期、监测及治疗反应评估：多层螺旋CT的作用
Abdom Imaging. 2014 Feb;39(1):66-85. doi: 10.1007/s00261-013-0037-1.
9
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.F-18氟脱氧葡萄糖正电子发射断层扫描在评估肾细胞癌远处转移中的应用
J Clin Oncol. 2003 Nov 1;21(21):3995-4000. doi: 10.1200/JCO.2003.04.073.
10
[Ipsilateral Occurrence of Renal Pelvic Carcinoma after Partial Nephrectomy for Renal Cell Carcinoma].肾细胞癌部分肾切除术后肾盂癌的同侧发生
Hinyokika Kiyo. 2016 Oct;62(10):535-537. doi: 10.14989/ActaUrolJap_62_10_535.
引用本文的文献
1
Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases.病例报告：晚期肾鳞状细胞癌伴肺转移患者的放化疗与免疫治疗联合应用
Front Immunol. 2025 Aug 8;16:1645909. doi: 10.3389/fimmu.2025.1645909. eCollection 2025.
2
Delayed Abscopal Response 3 Years After Robotic Stereotactic Body Radiation Therapy for Renal Cell Carcinoma: A Case Report.机器人立体定向体部放射治疗肾细胞癌3年后的延迟远隔效应：一例报告
Cancer Rep (Hoboken). 2025 May;8(5):e70229. doi: 10.1002/cnr2.70229.
3
Molecular mechanisms of renal cell carcinoma metastasis and potential targets for therapy.肾细胞癌转移的分子机制及潜在治疗靶点
Front Cell Dev Biol. 2025 Jan 20;13:1521151. doi: 10.3389/fcell.2025.1521151. eCollection 2025.
4
Pre-operative imaging evaluation of renal cell carcinoma.肾细胞癌的术前影像学评估。
Rev Assoc Med Bras (1992). 2024 Jun 7;70(suppl 1):e2024S107. doi: 10.1590/1806-9282.2024S107. eCollection 2024.
5
Characterization of Expression in Renal Cell Carcinoma.肾细胞癌中表达的特征分析。
Cancers (Basel). 2024 May 13;16(10):1855. doi: 10.3390/cancers16101855.
6
TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.TRIM26 通过使 ETK 不稳定从而使 AKT/mTOR 信号失活，抑制透明细胞肾细胞癌的进展。
J Transl Med. 2024 May 21;22(1):481. doi: 10.1186/s12967-024-05273-w.
7
Small Bowel Perforation Due to Renal Carcinoma Metastasis: A Comprehensive Case Study and Literature Review.肾癌转移导致小肠穿孔：一项综合病例研究及文献综述
Diagnostics (Basel). 2024 Apr 3;14(7):761. doi: 10.3390/diagnostics14070761.
8
Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study.转移性肾细胞癌患者能否从减瘤性肾切除术中获得生存益处？一项基于人群的研究。
J Cancer Res Clin Oncol. 2023 Sep;149(12):9657-9670. doi: 10.1007/s00432-023-04885-x. Epub 2023 May 25.
9
Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC).关于将肾细胞癌IV期/M1期重新划分为M1（“寡转移”）和M2（“多转移”）子域的两层分类法提案：转移性肾细胞癌登记处（REMARCC）分析
Front Oncol. 2023 Mar 29;13:1113246. doi: 10.3389/fonc.2023.1113246. eCollection 2023.
10
ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway.ADAM12 通过 EGFR/ERK 信号通路促进肾透明细胞癌的进展并引发 EMT。
J Transl Med. 2023 Jan 30;21(1):56. doi: 10.1186/s12967-023-03913-1.
本文引用的文献
1
Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.评估接受挽救性治疗的转移性肾细胞癌患者肿瘤反应的替代反应标准和临床风险因素
AJR Am J Roentgenol. 2017 Dec;209(6):1278-1284. doi: 10.2214/AJR.17.18018. Epub 2017 Oct 24.
2
Imaging and Screening of Kidney Cancer.肾癌的影像学检查与筛查
Radiol Clin North Am. 2017 Nov;55(6):1235-1250. doi: 10.1016/j.rcl.2017.06.007.
3
Renal Mass and Localized Renal Cancer: AUA Guideline.肾脏肿块和局限性肾细胞癌：AUA 指南。
J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.
4
The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.转移性肾细胞癌全身治疗的进展
Am Soc Clin Oncol Educ Book. 2016;35:113-7. doi: 10.1200/EDBK_158892.
5
RECIST 1.1-Update and clarification: From the RECIST committee.RECIST 1.1更新与说明：来自RECIST委员会。
Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.
6
ACR Appropriateness Criteria Renal Cell Carcinoma Staging.美国放射学会（ACR）肾细胞癌分期适宜性标准
J Am Coll Radiol. 2016 May;13(5):518-25. doi: 10.1016/j.jacr.2016.01.021. Epub 2016 Mar 23.
7
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.靶向PD-1/PD-L1治疗转移性肾细胞癌。
Ther Adv Urol. 2015 Dec;7(6):365-77. doi: 10.1177/1756287215597647.
8
Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma.磁共振成像作为肾细胞癌的生物标志物
Dis Markers. 2015;2015:648495. doi: 10.1155/2015/648495. Epub 2015 Nov 1.
9
Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.¹⁸F-DCFPyL靶向PSMA的PET/CT对转移性透明细胞肾细胞癌的成像
Ann Nucl Med. 2015 Dec;29(10):877-82. doi: 10.1007/s12149-015-1017-z. Epub 2015 Aug 19.
10
RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.在接受血管内皮生长因子靶向治疗的晚期肾细胞癌患者中，将实体瘤疗效评价标准（RECIST）1.1版与RECIST 1.0版进行比较。
AJR Am J Roentgenol. 2015 Mar;204(3):W282-8. doi: 10.2214/AJR.14.13236.
Zotero 插件